India, February 2026 — Senores Pharmaceuticals Limited has appointed Mr. Jatin Gajjar as its Chief Technology Officer (CTO). He assumed the role in February 2026 and will lead the company’s end-to-end technical strategy across R&D, formulation and analytical development, regulatory CMC, and technology transfer.
As CTO, Gajjar will oversee the development and scale-up of complex and conventional generic drug products, ensuring successful technology transfer to the company’s FDA-approved manufacturing facilities in India and the United States, as well as selected CMOs. He will integrate science, compliance, and commercial strategy to drive first-cycle approvals, robust tech transfer, cost-optimized manufacturing, and differentiated product development, while strengthening long-term technology platforms and regulatory engagement capabilities.
Prior to joining Senores Pharmaceuticals Limited, Gajjar served as President at QuoSolve. Earlier, he was President and Head – Global R&D at Eugia Pharma Specialities Ltd, where he led multiple R&D centers across India and the United States focused on specialty products including injectables, inhalations, ophthalmics, oral solids, long-acting injectables, peptides, and nano-particle drug delivery platforms for regulated markets.
He previously held the position of Senior Vice President and Head – Global R&D (India) at Endo International plc, supporting complex generics and 505(b)(2) projects for the US market, including solid oral dosage forms, complex sterile products, nasal sprays, and ophthalmics.
Gajjar also served as Executive Vice President and Head – R&D at Amneal Pharmaceuticals, where he led large multidisciplinary R&D teams across oral solids, parenteral, oncology, and ophthalmic segments. During his tenure, he oversaw the submission of more than 50 ANDAs in the US and numerous filings across Europe, Canada, and Australia, while successfully navigating multiple FDA Pre-Approval Inspections and EU audits.
His earlier leadership roles include senior R&D positions at Famy Care Ltd., Unimark Remedies Ltd., Sun Pharmaceutical Industries Ltd., Alembic Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Ltd., and Aventis Pharma, building deep expertise in formulation development, Quality-by-Design (QbD), regulatory strategy, technology transfer, and global product development.
With over three decades of experience in pharmaceutical R&D, technology platforms, and complex generics, Gajjar brings strong technical leadership to Senores Pharmaceuticals as it expands its niche and specialty portfolio in regulated markets.
About Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited is a global research-driven pharmaceutical company engaged in the development and manufacturing of pharmaceutical products primarily for the US, Canada, and other regulated and emerging markets.
Committed to innovation and international quality standards, Senores focuses on niche, complex, and specialty pharmaceutical products to support the evolving needs of the global healthcare industry.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
